Quince Therapeutics (QNCX) delays 2025 10-K after failed Phase 3; seeks 15-day extension

2026-04-13 01:53:36

Abstract generation in progress

Quince Therapeutics (QNCX) announced a delay in filing its 2025 Annual Report on Form 10-K, citing the need for additional time to complete accounting procedures due to recent headcount reductions and the negative results from a Phase 3 clinical trial. The company expects to file the report within the 15-calendar-day extension permitted by Rule 12b-25. This delay is attributed to the complexities arising from the failed Phase 3 study, which did not meet its primary endpoint, leading to strategic actions including staff reductions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.